Mutz Christopher's Form 4 filing
Ani Pharmaceuticals Inc (ANIP) · filed Mar 13, 2026
- Accession no.
- 0001846487-26-000014
- Filed
- Mar 13, 2026
- Trade date
- Mar 13, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $226.5K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mutz ChristopherCIK 0001846487 | Officer (HEAD OF RARE DISEASE) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Common Stock | SSaleDisposed | −3,162 | $71.64F2 | −$226,525.68 | 91,309 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.